Capsule Summary Slidesets


Share

Program Content

Activities

  • RATIFY 10-Yr Follow-Up
    CALGB 10603/RATIFY: 10-Yr Follow-up of Midostaurin vs Placebo Combined With Intensive CT for Newly Diagnosed FLT3-Mutant AML 
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2024

    Expires: December 09, 2025

  • ASC4FIRST Asciminib
    ASC4FIRST: Phase III Trial of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor as First-line Therapy for Chronic Myeloid Leukemia in Chronic Phase
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2024

    Expires: December 10, 2025

  • ASCEND CML
    ASCEND-CML: Update From Phase II Trial of Frontline Asciminib in Patients With CP-CML
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2024

    Expires: December 12, 2025

  • CLAD LDAC VEN in ND AML
    Phase II Trial of Cladribine + LDAC + Venetoclax Alternating With Azacitidine + Venetoclax in Patients With Newly Diagnosed AML
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2024

    Expires: December 12, 2025

  • GIMEMA ALL2820
    GIMEMA ALL2820: Intermediate Analysis of Phase III Trial of First-line Ponatinib + Blinatumomab in Adults With Ph+ Acute Lymphoblastic Leukemia
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2024

    Expires: December 12, 2025

  • Revumenib in Acute Leukemias
    AUGMENT-101 and SAVE: Revumenib-Based Therapy in R/R Acute Leukemias
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2024

    Expires: December 15, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation